<DOC>
	<DOCNO>NCT00776243</DOCNO>
	<brief_summary>In type 2 diabetic patient , abnormality secretion action incretin ( GLP-1 , GIP ) observe . Although controversy still exist , secretion GLP-1 thought reduce 20-30 % GIP secretion normal slightly elevate , type 2 diabetic patient . Various parameter duration diabetes , amount meal constitution , gastric bypass surgery , antidiabetic drug affect secretion incretin . However , secretion GLP-1 GIP glucotoxic condition whether recover improvement glycemic status know . The investigator aim study effect intensive insulin treatment uncontrolled diabetic patient .</brief_summary>
	<brief_title>Short-term Effect Intensive Insulin Therapy Incretin Secretion</brief_title>
	<detailed_description />
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<criteria>type 2 diabetic patient disease duration le 15years age 2070 year BMI 2227 HbA1c 913 % patient willing receive intensive glucose control patient able monitor glucose level home normal glucose tolerance group : NGT subject range age BMI early diabetes group : patient diabetic duration le 5 year HbA1c level le 7.5 % least last 6 month previous history insulin treatment patient take alphaglucosidase inhibitor thiazolidinedione serum creatinine &gt; = 1.5 mg/dL hemoglobin &lt; 10 g/dL AST/ALT great 3 time normal range ischemic heart disease , congestive heart failure ( NYHA grade &gt; =2 ) chronic renal failure , proliferative diabetic retinopathy , CVA patient gastroparesis take medication alter gastric motility usage steroid agent affect glucose metabolism pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>incretin</keyword>
	<keyword>GLP-1</keyword>
	<keyword>GIP</keyword>
	<keyword>intensive insulin therapy</keyword>
</DOC>